ONC BeOne Medicines Ltd.
Nasdaq · SEC CIK 1651308 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $361.20M 49 sales by 12 insiders
- Filings on record
- 271 since 2021-07-01, latest 2026-09-10 16:49
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| OYLER JOHN | CEO, Dir | — | $327.88M |
| Wang Xiaodong | Dir, COB, Scientific Advisory Brd | — | $13.37M |
| Wu Xiaobin | Pres, COO | — | $8.75M |
| Lee Chan Henry | SVP, GC | — | $7.95M |
| Wang Lai | Pres, Gbl Head of R, D | — | $1.17M |
| Sanders Corazon (Corsee) D. | Dir | — | $961.2K |
| Rosenberg Aaron | CFO | — | $524.4K |
| BAKER BROS. ADVISORS LP | Dir | — | $262.0K |
| Ball Titus B. | Principal Accounting Off | — | $127.3K |
| Dugan Margaret | Dir | — | $65.6K |
Transactions 336
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-05-06 | 2022-05-05 | ONC | Wu Xiaobin | Pres, COO, GM China | S - Sale | $164.35 | -6,725 | 1,300 | -84% | -$1.11M |
| 2022-03-02 | 2022-02-28 | ONC | Wang Julia Aijun | CFO | A - Grant | $0.00 | +61.8K | 143.3K | +76% | $0 | |
| I | 2021-12-17 | 2021-12-15 | ONC | Wu Xiaobin | Pres, COO, GM China | A - Grant | — | 0 | 0 | New | — |
| I | 2021-12-17 | 2021-12-15 | ONC | Wang Lai | Gbl Head of R, D | A - Grant | — | 0 | 0 | New | — |
| MI | 2021-12-17 | 2021-10-31 | ONC | Wang Lai | Gbl Head of R, D | G - Gift | $0.00 | 0 | 58.2K | New | $0 |
| 2021-12-17 | 2021-09-28 | ONC | Wang Lai | Gbl Head of R, D | G - Gift | $0.00 | -58.2K | 174.6K | -25% | $0 | |
| DM | 2021-12-16 | 2021-12-14 | ONC | Huang Jane | CMO, Hematology | S - Sale+OE | $278.14 | -1,500 | 400 | -79% | -$417.2K |
| D | 2021-12-16 | 2021-12-14 | ONC | Huang Jane | CMO, Hematology | M - OptEx | $119.96 | +1,500 | 1,500 | New | +$179.9K |
| M | 2021-12-02 | 2021-11-30 | ONC | Huang Jane | CMO, Hematology | A - Grant | $0.00 | +15.9K | 1,049 | New | $0 |
| M | 2021-12-02 | 2021-12-01 | ONC | Huang Jane | CMO, Hematology | S - Sale | $359.86 | -1,049 | 519 | -67% | -$377.5K |
| D | 2021-11-19 | 2021-11-17 | ONC | Huang Jane | CMO, Hematology | M - OptEx | $119.96 | +1,500 | 1,500 | New | +$179.9K |
| DM | 2021-11-19 | 2021-11-17 | ONC | Huang Jane | CMO, Hematology | S - Sale+OE | $381.34 | -1,500 | 400 | -79% | -$572.0K |
| M | 2021-11-10 | 2021-11-08+ | ONC | Wu Xiaobin | Pres, COO, GM China | S - Sale | $358.27 | -10.0K | 5,433 | -65% | -$3.58M |
| M | 2021-11-10 | 2021-11-08 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | S - Sale | $349.81 | -4,500 | 4,200 | -52% | -$1.57M |
| M | 2021-11-10 | 2021-11-08 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | S - Sale | $350.04 | -4,500 | 1,300 | -78% | -$1.58M |
| DM | 2021-10-21 | 2021-10-19 | ONC | Huang Jane | CMO, Hematology | S - Sale+OE | $372.78 | -1,500 | 1,200 | -56% | -$559.2K |
| D | 2021-10-21 | 2021-10-19 | ONC | Huang Jane | CMO, Hematology | M - OptEx | $119.96 | +1,500 | 1,500 | New | +$179.9K |
| D | 2021-09-22 | 2021-09-20 | ONC | Huang Jane | CMO, Hematology | M - OptEx | $119.96 | +6,000 | 6,000 | New | +$719.8K |
| DM | 2021-09-22 | 2021-09-20 | ONC | Huang Jane | CMO, Hematology | S - Sale+OE | $397.96 | -6,000 | 5,900 | -50% | -$2.39M |
| M | 2021-09-16 | 2021-09-14+ | ONC | OYLER JOHN | CEO, Dir | S - Sale | $82.04 | -411.8K | 1.74M | -19% | -$33.79M |
| M | 2021-09-15 | 2021-09-13 | ONC | Huang Jane | CMO, Hematology | S - Sale | $358.14 | -12.9K | 1,582 | -89% | -$4.62M |
| 2021-09-13 | 2021-09-10 | ONC | AMGEN INC | 10% | P - Purchase | $302.06 | +165.5K | 18.94M | +0.9% | +$50.00M | |
| M | 2021-09-02 | 2021-08-31+ | ONC | Huang Jane | CMO, Hematology | A - Grant | $0.00 | +15.4K | 305.8K | +5% | $0 |
| M | 2021-09-02 | 2021-09-01+ | ONC | Huang Jane | CMO, Hematology | S - Sale | $318.88 | -1,087 | 0 | -100% | -$346.6K |
| M | 2021-09-02 | 2021-08-31+ | ONC | OYLER JOHN | CEO, Dir | S - Sale | $109.77 | -288.6K | 23.5K | -92% | -$31.69M |
| M | 2021-08-05 | 2021-08-04+ | ONC | OYLER JOHN | CEO, Dir | S - Sale | $132.34 | -125.3K | 1,600 | -99% | -$16.58M |
| M | 2021-08-05 | 2021-08-03 | ONC | OYLER JOHN | CEO, Dir | S - Sale | $182.37 | -83.4K | 20.5K | -80% | -$15.20M |
| M | 2021-07-22 | 2021-07-20+ | ONC | OYLER JOHN | CEO, Dir | S - Sale | $152.13 | -70.9K | 10.2K | -87% | -$10.78M |
| M | 2021-07-22 | 2021-07-22 | ONC | OYLER JOHN | CEO, Dir | S - Sale | $71.82 | -69.2K | 516 | -99% | -$4.97M |
| DM | 2021-07-19 | 2021-07-15 | ONC | Huang Jane | CMO, Hematology | M - OptEx | $146.90 | +21.0K | 6,914 | New | +$3.09M |
| DM | 2021-07-19 | 2021-07-15 | ONC | Huang Jane | CMO, Hematology | S - Sale+OE | $332.42 | -21.0K | 0 | -100% | -$6.98M |
| M | 2021-07-08 | 2021-07-06+ | ONC | OYLER JOHN | CEO, Dir | S - Sale | $117.22 | -123.8K | 1,457 | -99% | -$14.51M |
| M | 2021-07-08 | 2021-07-07+ | ONC | OYLER JOHN | CEO, Dir | S - Sale | $94.83 | -67.5K | 10.3K | -87% | -$6.40M |
| M | 2021-07-08 | 2021-07-06 | ONC | Wu Xiaobin | Pres, COO, GM China | S - Sale | $325.53 | -10.2K | 0 | -100% | -$3.31M |
| 2021-07-01 | 2021-07-01 | ONC | Wang Julia Aijun | CFO | S - Sale | $349.06 | -308 | 0 | -100% | -$107.5K | |
| M | 2021-07-01 | 2021-07-01 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | S - Sale | $348.16 | -4,848 | 0 | -100% | -$1.69M |
Purchase Sale Sale after option exercise All abbreviations